Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 24, 2014; 4(2): 133-140
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.133
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.133
Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients
Ainhoa Fernández-Yunquera, Cristina Ripoll, Rafael Bañares, Diego Rincón, Ismael Yepes, Vega Catalina, Magdalena Salcedo, Department of Liver Transplantation, Hospital General Gregorio Marañón, 28028 Madrid, Spain
Rafael Bañares, Marta Puerto, Diego Rincón, On-Line Biomedical Investigation Center for Hepatic and Gastrointestinal Diseases, 28028 Madrid, Spain
Author contributions: Fernández-Yunquera A performed the study and wrote the paper; Ripoll C analyzed the data, wrote the paper and gave final approval of the version to be published; Bañares R analyzed and interpreted the data; Puerto M contributed important reagents; Rincón D, Yepes I and Catalina C collected the data; and Salcedo M designed the study.
Supported by Novartis Pharma Schweiz AG
Correspondence to: Magdalena Salcedo, Chief Doctor, Department of Liver Transplantation, Hospital General Gregorio Marañón, C/ Doctor Esquerdo nº 46, 28028 Madrid, Spain. magdalena.salcedo@salud.madrid.org
Telephone: +34-630-991228 Fax: +34-91-5868308
Received: October 30, 2013
Revised: January 29, 2014
Accepted: February 18, 2014
Published online: June 24, 2014
Revised: January 29, 2014
Accepted: February 18, 2014
Published online: June 24, 2014
Core Tip
Core tip: This study tries to approach the possible antifibrotic effect of everolimus, a mammalian target of a rapamycin inhibitor, in the clinical setting. Some studies in animal models suggest that it could also have an antifibrotic effect. The main conclusion of this study is that liver transplantation recipients with everolimus monotherapy had less serum expression of transforming growth factor-β and hyaluronic acid than matched patients with anti-calcineurins that play an important role in liver fibrosis. The study offers the rationale for much needed future randomized controlled trials that evaluate the modulation of post-transplant fibrosis.